COMPANY:

Datar Cancer Genetics

"Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte AI-driven platform providing optimized treatment options for cancer patients who have exhausted the standard options....Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity, and contraindications for Anti-body Drug Conjugates (ADC)s, Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy agents and repurposed drugs. It can recommend up to 10 evidence-based multi-drug treatment combinations for evaluation by oncologists or molecular tumor boards (MTBs), offering new hope where no standard of care exists for refractory / recurrent cancer patients."

"Datar Cancer Genetics...announced its partnership with Goodbody Health Limited (Goodbody Health) to offer its innovative Circulating Tumor Cell (CTC) based multi-cancer screening solution Trucheck in the UK."

"Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Glio', a blood test to help in the diagnosis of brain tumors. This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA. The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation....A prospective, blinded study by a research team at the Imperial College, London, showed the test to be highly accurate. The test requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful."

"Datar Cancer Genetics said...that it has struck a $250 million contract with US diagnostic laboratory company Artemis DNA, which will provide Datar's cancer detection liquid biopsies in the US and Vietnam...The five-year exclusive agreement covers two Datar cancer screening and diagnostic tests: Trucheck Pragma, a noninvasive, blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; and Cancertrack, which evaluates therapy response, resistance, and cancer recurrence in patients. The assays will be initially offered as laboratory-developed tests in the US, according to Datar."

"Starting April 2022, Artemis DNA will begin offering its genetic testing technology and portfolio, as well as a new, revolutionary cancer screening called Trucheck™ Pragma through a partnership with Datar Cancer Genetics (Datar)...Under the partnership, Artemis DNA will be the exclusive distributor for Trucheck™ Pragma in Vietnam. Datar will support the successful rollout of the cancer screening solution, which has been proven through extensive clinical validations involving more than 40,000 participants."

"Datar Cancer Genetics has announced its partnership with The London Clinic...to provide precision oncology-based solutions to improve the detection and treatment of cancers. The partnership brings together two organisations that are dedicated to finding ever better ways to detect and treat cancers for the betterment of patients around the world."

"Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage prostate cancer...The test has previously received CE certification and is already available in Europe as 'Trublood-Prostate'. The UK-NICE last year issued a MedTech Innovation Briefing that described the Test as a 'Game Changer'."

"Datar Cancer Genetics...announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™' blood test to detect early-stage Breast Cancer...TriNetra™ uses a proprietary technology developed by the Company to detect Circulating Tumor Cells (CTCs) specific to Breast Cancer. Studies have shown that TriNetra™ can detect even Stage 0 (DCIS) and Stage 1 cancers with high accuracy. The test requires only 5 ml blood and is indicated for asymptomatic women above the age of 40 years with a physician's prescription."